Best Practices for the Design, Implementation, Analysis, and Reporting of Oncology Trials with High Rates of Treatment Switching

GPC released a report that provides guidance for researchers who lead oncology drug trials that may involve substantial treatment switching. Treatment switching most often occurs when a patient moves from the control to the experimental group during a clinical trial – for example, because the patient’s disease has progressed and they want to try the experimental treatment.

The guidance document and development process are available for download on the right.  An overview of the initiative is available here